Moonlake Immunotherapeutics Announced Landmark Phase 2 Results For Nanobody Sonelokimab In Active Psoriatic Arthritis; Primary Endpoint; Key Secondary Endpoints Met
Portfolio Pulse from Charles Gross
MoonLake Immunotherapeutics (NASDAQ:MLTX) announced positive top-line results from its global Phase 2 ARGO trial evaluating the efficacy and safety of the Nanobody® sonelokimab in patients with active psoriatic arthritis. The primary endpoint ACR50 was met with up to 47% of patients on sonelokimab achieving ACR50 as early as week 12. All key secondary endpoints were also met. The discontinuation rate was below 4% and safety results were consistent with previously reported studies.
November 05, 2023 | 4:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MoonLake's positive trial results for sonelokimab could potentially boost its stock in the short term as it indicates progress in the company's product pipeline.
Positive clinical trial results often lead to increased investor confidence and can drive up a company's stock price. Given that the trial met both its primary and secondary endpoints, this is likely to be viewed as a significant positive development for MoonLake.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100